Jeremy Bender - Aug 15, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Aug 15, 2022
Transactions value $
-$97,313
Form type
4
Date filed
8/17/2022, 07:24 PM
Previous filing
Aug 5, 2022
Next filing
Sep 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise $0 +10.7K +0.86% $0.00 1.26M Aug 15, 2022 Direct
transaction DAWN Common Stock Sale -$97.3K -4K -0.32% $24.31 1.25M Aug 16, 2022 Direct F1
holding DAWN Common Stock 282K Aug 15, 2022 See Footnote F2
holding DAWN Common Stock 282K Aug 15, 2022 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -10.7K -18.75% $0.00 46.3K Aug 15, 2022 Common Stock 10.7K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").
F2 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F3 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
F4 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F5 The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.